Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cutaneous squamous cell carcinoma
Pharma
Checkpoint passes FDA checkpoint for PD-L1 drug Unloxcyt
While Unloxcyt is the first PD-L1 inhibitor for CSCC, Regeneron’s Libtayo and Merck’s Keytruda are already available in the indication.
Angus Liu
Dec 16, 2024 10:59am
Merck’s Keytruda flunks pivotal studies in lung and skin cancers
Aug 29, 2024 10:16am
NICE signs off on Libtayo for skin cancer type
May 26, 2022 10:58am
Merck treads on Sanofi, Regeneron's turf with Keytruda OK
Jun 24, 2020 4:42pm
